

Embrace

Role of Targeted Therapy
in Metastatic Breast Cancer

In Canada, 5–10% of newly diagnosed breast cancers are metastatic, and among those first diagnosed with early stage breast cancer, there's approximately a 20–30% chance of developing metastatic breast cancer (MBC).^{1,2}

What

EMBRACE is a brand new MBC learning program designed by an engaged and highly experienced Steering Committee of fellow oncology nurses. Understanding the targeted audience for this program are busy and expected to stay up-to-date with the latest treatment options to optimally support their patients, EMBRACE was built with flexible modules to allow for short or in-depth discussions.

The program includes an overview of MBC, clinical evidence for available treatment options, and opportunities for reflection on clinical practice, using case-based learning techniques.

Who

This important learning program is for all nurses who interact and care for patients with MBC.

Why

New targeted agents have been recently approved and education is needed to understand their mechanism of action, place in therapy, efficacy and tolerability. At the conclusion of this program, participants should be able to:

- Define the prevalence and impact of breast cancer and metastatic breast cancer (MBC)
- Discuss treatment guidelines, and currently available treatments for ER and/or PR+, HER2- breast cancer
- Explain the mechanism of action, efficacy, and safety of new targeted therapies
- Counsel patients on adverse events, and know the dosing and monitoring recommendations for patients receiving new targeted therapies

Program Steering Committee

This learning program was developed by the following experts in the field leveraging regional input from across Canada:

Edith Pituskin, RN, MN (NP Adult) PhD
Assistant Professor
University of Alberta, Edmonton, AB

Nancy Gregorio, BScN, MN, OCN, CON(C)
Nurse Coordinator
Princess Margaret, Toronto, ON

Program Endorsement

This program meets Canadian Association of Nurses in Oncology (CANO) guidelines and is expected to support nurses in their understanding of metastatic breast cancer. Endorsement is provided by CANO for a time period of one year, ending September/2019.



Under the guidance of Innovative Medicines Canada's Code of Ethical Practices, this event is for healthcare professionals only.

1. Canadian Partnership Against Cancer. Breast Cancer Control in Canada: A System Performance Special Focus Report. September 2012.

Available at: https://content.cancerview.ca/download/cv/quality_and_planning/system_performance/documents/breastcancercontrolreppdf?attachment=0. Accessed May 01, 2018

2. Canadian Breast Cancer Foundation. Metastatic Breast Cancer. Available at: <http://www.cbcf.org/central/AboutBreastCancerMain/MetastaticBreastCancer/Pages/Metastatic-Breast-Cancer.aspx>. Accessed May 01, 2018